Turning cold tumors hot: from molecular mechanisms to clinical applications

J Zhang, D Huang, PE Saw, E Song - Trends in immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Hepatocellular carcinoma immune landscape and the potential of immunotherapies

J Giraud, D Chalopin, JF Blanc, M Saleh - Frontiers in immunology, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the most common liver tumor and among the deadliest
cancers worldwide. Advanced HCC overall survival is meager and has not improved over …

Predictive biomarkers of colon cancer immunotherapy: Present and future

W Hou, C Yi, H Zhu - Frontiers in immunology, 2022 - frontiersin.org
Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

HD Kim, S Jung, HY Lim, BY Ryoo, MH Ryu, S Chuah… - Nature Medicine, 2024 - nature.com
Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma
(uHCC) with potential immunomodulatory effects, suggesting that its combination with …

The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy

J Stagg, E Golden, E Wennerberg, S Demaria - Science immunology, 2023 - science.org
The extracellular nucleoside adenosine reduces tissue inflammation and is generated by
irreversible dephosphorylation of adenosine monophosphate (AMP) mediated by the …

Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular …

X Zhang, J Zhuge, J Liu, Z **a, H Wang, Q Gao… - Frontiers in …, 2023 - frontiersin.org
Background Hepatocellular carcinoma (HCC) is a complex disease with a poor outlook for
patients in advanced stages. Immune cells play an important role in the progression of HCC …

[HTML][HTML] Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma

CL Hsu, DL Ou, LY Bai, CW Chen, L Lin, SF Huang… - Liver cancer, 2021 - karger.com
Background: Reversal of CD8 T-cell exhaustion was considered a major antitumor
mechanism of anti-programmed cell death-1 (PD-1)/anti-programmed death ligand-1 (PD …

[HTML][HTML] Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy

RC Augustin, RD Leone, A Naing, L Fong… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Increasing evidence supports targeting the adenosine pathway in immuno-oncology with
several clinical programs directed at adenosine A2 receptor (A2AR, A2BR), CD73 and …

Case report: persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID

D Goh, JCT Lim, SB Fernaíndez, CR Joseph… - Frontiers in …, 2022 - frontiersin.org
The World Health Organization has defined long COVID-19 (LC) as a condition that occurs
in individuals with a history of SARS-CoV-2 infection who exhibit persistent symptoms after …

Full spectrum flow cytometry as a powerful technology for cancer immunotherapy research

DL Bonilla, G Reinin, E Chua - Frontiers in Molecular Biosciences, 2021 - frontiersin.org
The Nobel Prize-deserving concept of blocking inhibitory pathways in T cells, to unleash
their anti-tumoral capacity, became one of the pillars of cancer treatment in the last decade …